{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:13:22Z","timestamp":1771503202947,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40122-025-00719-5","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:47:21Z","timestamp":1743961641000},"page":"1045-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-4547","authenticated-orcid":false,"given":"Caroline S.","family":"Casey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4798-1512","authenticated-orcid":false,"given":"Mari","family":"P\u00f6lkki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5255-4115","authenticated-orcid":false,"given":"Elisa K.","family":"Suvanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7429-3279","authenticated-orcid":false,"given":"Ilona","family":"Iso-Mustaj\u00e4rvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-7495","authenticated-orcid":false,"given":"Timo","family":"Purmonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-3089","authenticated-orcid":false,"given":"Essi J.","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-7152","authenticated-orcid":false,"given":"Camilla K.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-9374","authenticated-orcid":false,"given":"Niraj J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-6268","authenticated-orcid":false,"given":"Lill-Brith","family":"Von Arx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"issue":"Suppl 1","key":"719_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332.","journal-title":"Headache"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s10194-020-01185-4","volume":"21","author":"M-L Sumelahti","year":"2020","unstructured":"Sumelahti M-L, Sumanen M, Sumanen MS, et al. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain. 2020;21:118.","journal-title":"J Headache Pain"},{"key":"719_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133\u201361.","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40120-021-00303-x","volume":"11","author":"H Autio","year":"2022","unstructured":"Autio H, Purmonen T, Kurki S, Mocevic E, Korolainen MA, Tuominen S, et al. Erenumab decreases headache-related sick leave days and health care visits: a retrospective real-world study in working patients with migraine. Neurol Ther. 2022;11:223\u201335.","journal-title":"Neurol Ther."},{"issue":"2 Suppl","key":"719_CR5","first-page":"S23","volume":"25","author":"GL Peters","year":"2019","unstructured":"Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23\u201334.","journal-title":"Am J Manag Care"},{"key":"719_CR6","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17:174\u201382.","journal-title":"Lancet Neurol"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW. Migraine. Lancet. 2018;391:1315\u201330.","journal-title":"Lancet"},{"key":"719_CR9","unstructured":"Rashid A, Manghi A. Calcitonin Gene-Related Peptide Receptor. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560648\/. Accessed January 2024."},{"key":"719_CR10","unstructured":"Erenumab: Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed December 2023."},{"key":"719_CR11","unstructured":"Galcanezumab: Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emgality-epar-product-information_en.pdf. Accessed December 2023."},{"key":"719_CR12","unstructured":"Fremanezumab: Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf. Accessed December 2023."},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11916-015-0498-8","volume":"19","author":"EK Seng","year":"2015","unstructured":"Seng EK, Rains JA, Nicholson RA, Lipton RB. Improving medication adherence in migraine treatment. Curr Pain Headache Rep. 2015;19:24.","journal-title":"Curr Pain Headache Rep"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1038\/s41598-023-30854-y","volume":"13","author":"F Rimmele","year":"2023","unstructured":"Rimmele F, M\u00fcller B, Becker-Hingst N, et al. Medication adherence in patients with cluster headache and migraine: an online survey. Sci Rep. 2023;13:4546.","journal-title":"Sci Rep"},{"key":"719_CR15","unstructured":"Kela [Internet]. [cited 2023 May 24]. 3007 Eptinetsumabi, erenumabi, fremanetsumabi ja galkanetsumabi. Available from: https:\/\/www.kela.fi\/laake3007"},{"key":"719_CR16","unstructured":"Hila 2020. Korvausj\u00e4rjestelm\u00e4\u00e4n hyv\u00e4ksytyt valmisteet [Medicinal products approved for the reimbursement system] 2020. Available from: https:\/\/www.hila.fi\/luettelot\/korvausjarjestelmaan-hyvaksytyt-valmisteet\/2020-2\/. Accessed February 2024."},{"key":"719_CR17","unstructured":"Galen Research 2023. Measures database. Available from: https:\/\/galen-research.com\/measures-database\/. Accessed December 2023."},{"key":"719_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2165\/00044011-199815050-00006","volume":"15","author":"SP McKenna","year":"1998","unstructured":"McKenna SP, Doward LC, Davey KM. The development and psychometric properties of the MSQOL: A migraine-specific quality-of-life instrument. Clin Drug Investig. 1998;15:413\u201323.","journal-title":"Clin Drug Investig"},{"key":"719_CR19","unstructured":"Intersoft Consulting 2024. Art. 9 GDPR Processing of special categories of personal data. Available from: https:\/\/gdpr-info.eu\/art-9-gdpr\/. Accessed February 2024."},{"key":"719_CR20","unstructured":"Finnish National Board on Research Integrity TENK. The ethical principles of research with human participants and ethical review in the human sciences in Finland. Finnish National Board on Research Integrity TENK guidelines 2019. Available from: https:\/\/tenk.fi\/sites\/default\/files\/2021-01\/Ethical_review_in_human_sciences_2020.pdf. Accessed February 2024."},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER Trial. Adv Ther. 2021;38:5465\u201383.","journal-title":"Adv Ther"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280\u20137.","journal-title":"Lancet"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"key":"719_CR24","unstructured":"Duodecim K\u00e4yp\u00e4 Hoito 2024. Migreeni [Migraine]. Available from: https:\/\/www.kaypahoito.fi\/hoi36050?tab=suositus. Accessed February 2024."},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78:589\u2013600.","journal-title":"Drugs"},{"key":"719_CR26","unstructured":"Electronic Medicines Compendium 2024. BOTOX 100 Allergan Units Powder for solution for injection. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/859\/smpc#gref. Accessed March 2024."},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-019-0964-5","volume":"20","author":"MA Korolainen","year":"2019","unstructured":"Korolainen MA, Kurki S, Lassenius MI, et al. Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019;20:13.","journal-title":"J Headache Pain"},{"issue":"8","key":"719_CR28","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s11136-006-0020-1","volume":"15","author":"SI Saarni","year":"2006","unstructured":"Saarni SI, H\u00e4rk\u00e4nen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15(8):1403\u201314.","journal-title":"Qual Life Res"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-020-1077-x","volume":"21","author":"MA Korolainen","year":"2020","unstructured":"Korolainen MA, Tuominen S, Kurki S, et al. Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare. J Headache Pain. 2020;21:8.","journal-title":"J Headache Pain"},{"key":"719_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.232","volume":"3","author":"CE Kleyn","year":"2023","unstructured":"Kleyn CE, McKenzie R, Meeks A, Gittens B, von Arx L-B. Prevalence and treatment patterns of adult atopic dermatitis in the UK Clinical Practice Research Datalink. Skin Health Dis. 2023;3: e232.","journal-title":"Skin Health Dis"},{"key":"719_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s43045-023-00340-2","volume":"30","author":"M Swathi","year":"2023","unstructured":"Swathi M, Manjusha S, Isatin JV, Guraraj A. Prevalence and correlates of stress, anxiety, and depression in patients with chronic diseases: a cross-sectional study. Middle East Curr Psychiatry. 2023;30:66.","journal-title":"Middle East Curr Psychiatry"},{"key":"719_CR32","doi-asserted-by":"publisher","first-page":"111040","DOI":"10.1016\/j.jpsychores.2022.111040","volume":"162","author":"B Liao","year":"2022","unstructured":"Liao B, Xu D, Tan Y, Chen X, Cai S. Association of mental distress with chronic diseases in 1.9 million individuals: a population-based cross-sectional study. J Psychosom Res. 2022;162:111040.","journal-title":"J Psychosom Res."},{"key":"719_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2023-003779","author":"J Talbot","year":"2024","unstructured":"Talbot J, Stuckey R, Wood N, Gordon A, Crossingham G, Weatherby S. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. Eur J Hosp Pharm. 2024. https:\/\/doi.org\/10.1136\/ejhpharm-2023-003779.","journal-title":"Eur J Hosp Pharm."},{"key":"719_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/WNL.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, et al. Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine\u2014clinical considerations. A narrative review. Neurology. 2022;99:841\u201353.","journal-title":"Neurology"},{"key":"719_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/jcm9020320","volume":"9","author":"JOT Sipil\u00e4","year":"2020","unstructured":"Sipil\u00e4 JOT, Ruuskanen JO, Rautava P, Kyt\u00f6 V. Adult migraine hospital admission trends in Finland: a nationwide registry study. J Clin Med. 2020;9:320.","journal-title":"J Clin Med"},{"key":"719_CR36","unstructured":"Statistical Database Kelasto. Filled prescriptions of reimbursable medicines according to prescriber. Available from: https:\/\/tietotarjotin.fi\/en\/statistical-data\/2051231\/statistical-database-kelasto. Accessed January 2024."},{"key":"719_CR37","unstructured":"Eptinezumab: Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyepti-epar-product-information_en.pdf. Accessed February 2024."}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00719-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:23:08Z","timestamp":1747473788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00719-5","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Caroline Casey and Niraj Patel are employees of Eli Lilly and Company and holders of Eli Lilly stock. Elisa Suvanen is an employee of Oy Eli Lilly Finland Ab and holder of Eli Lilly stock. Camilla Appel and Lill-Brith Von Arx are employees of Eli Lilly Danmark and holders of Eli Lilly stock. Mari P\u00f6lkki, Ilona Iso-Mustaj\u00e4rvi, Timo Purmonen, and Essi Peltonen are employees of Oriola Finland Oy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki 1964 and its later amendments and that are consistent with Good Pharmacoepidemiology Practices and applicable Finnish laws and regulations. A privacy statement following the European Union General Data Protection Regulation (Intersoft Consulting 2024) was available online for the respondents. The survey, including the pilot, was conducted according to the guidelines of the Finnish National Advisory Board on Research Integrity, which do not require ethics committee approval for surveys targeting respondents aged\u2009\u2265\u200915\u00a0years [].Participation in the study was anonymous and entirely voluntary. Respondents provided informed consent for the use of their responses in the study (via a checkbox on the electronic survey) and were able to withdraw consent at any time when completing the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}